Skip to main content
SpringerLink
Log in

Relationship Between Decrease in Ambulatory Blood Pressure and Heart Rate Variability Due to the Effects of Taking Olmesartan Medoxomil

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and methods: A higher degree of clinical efficacy with olmesartan compared with other angiotensin receptor blockers, has been reported by several sources. In this study of 31 examples of cases of essential hypertension, Holter electrocardiogram, ambulatory blood pressure monitoring and pulse wave velocity (PWV) measurements were performed before and after substituting olmesartan 20 mg for candesartan 8 mg antihypertensive drug therapy.

Results: Following the therapeutic change, daily average systolic and diastolic blood pressures were decreased by 6.7 ± 9.3 mmHg and 3.6 ± 8.3 mmHg, respectively, with olmesartan 20 mg; PWV was also significantly decreased. Holter electrocardiogram heart rate variability spectral analysis demonstrated that none of the very low frequency (VLF), high frequency (HF) and low frequency (LF)/HF components were significantly altered. However, a significant correlation was observed between the LF/HF component and blood pressure difference, when blood pressure and heart rate variability components in each individual case were studied.

Conclusion: This study shows that olmesartan has a stronger antihypertensive effect in comparison to candesartan, and does not generate reflex sympathoexcitatory activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582–7

    Article  PubMed  CAS  Google Scholar 

  2. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667–75

    Article  PubMed  CAS  Google Scholar 

  3. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759–66

    Article  PubMed  CAS  Google Scholar 

  4. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26Suppl. A: A33–7

    Article  PubMed  CAS  Google Scholar 

  5. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006; 26(4): 185–93

    Article  CAS  Google Scholar 

  6. Hiromichi S. Examination of the clinical usefulness of various angiotensin receptor blockers in regard to treatment of hypertension that accompanies nephropathy. Prog Med 2006; 26: 1669–75

    Google Scholar 

  7. Taiji S, Misako T, Tatsuya O, et al. Examination with regard to the effects of olmesartan on hypertension patients with diabetic complications. Prog Med 2006; 26: 475–9

    Google Scholar 

  8. Shinji T, Masato O, Satoshi M, et al. Blood pressure survey of essential hypertension patients in the early morning, ambulatory period and at night: ATOM Research. Pharmacol Treat 2004; 32: 481–6

    Google Scholar 

  9. Mitera T, Saitou M, Satou T, et al. 24-hour blood pressure and time course of heart rate variability changes in regard to 3 kinds of dihydropyridine-type Ca2+ channel blockers. Electrocardiogram 2001; 21: 481–90

    Google Scholar 

  10. Keishi A, Iwao K, Yutaka I, et al. Effects of the long-acting type Ca blocker balnidipine hydrochloride on blood pressure circadian rhythm: large-scale clinical trial J-MUBA. Final results. Ther Res 1999; 20: 2697–713

    Google Scholar 

  11. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6(10): 569–77

    Article  CAS  Google Scholar 

  12. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3(5): 283–91, 318

    Article  CAS  Google Scholar 

  13. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other anti-hypertensive agents: olmesartan medoxomil versus anti-hypertensives. J Hypertens Suppl. 2001; 19(1): S49–56

    PubMed  CAS  Google Scholar 

  14. Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1: 115–21

    Article  CAS  Google Scholar 

  15. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92(5): 1326–31

    Article  PubMed  CAS  Google Scholar 

  16. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39(1): 10–5

    Article  PubMed  CAS  Google Scholar 

  17. Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34(5): 1203–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was originally published in Japanese in Therapeutic Research [2007; 28 (5): 875–81]. The study has been reproduced here in English with kind permission of the publishers, Life Science Publishing Co., Ltd. Daiichi Sankyo provided financial assistance for the translation of this paper.

No funding was used to support the conduct of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, School of Medicine, Teikyo University, Teikyo, Japan

    Taiji Furukawa, Taketo Hatsuno, Yasunari Ueno, Kensuke Nagaoka, Yuji Watari, Takeshi Yamakawa, Toshio Sagawa & Takaaki Isshiki

Authors
  1. Taiji Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taketo Hatsuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasunari Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kensuke Nagaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuji Watari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Yamakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshio Sagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takaaki Isshiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furukawa, T., Hatsuno, T., Ueno, Y. et al. Relationship Between Decrease in Ambulatory Blood Pressure and Heart Rate Variability Due to the Effects of Taking Olmesartan Medoxomil. Clin. Drug Investig. 29, 257–264 (2009). https://doi.org/10.2165/00044011-200929040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200929040-00004

Keywords

Search

Navigation